Natera Inc. (NASDAQ:NTRA) said a federal court in Delaware has ruled that the company is entitled to a 30% ongoing royalty on ...

Natera (NTRA) has moved into focus after a favorable patent ruling against ArcherDx and Invitae, royalty income tied to MRD products, broad uptake of its Signatera test, and recent progress toward ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent ...

A social media post from the US Food and Drug Administration this week shows a big-eyed macaque staring out from behind bars. “Some drugs use 144 monkeys on average for preclinical testing,” the post ...

Natera Inc. NTRA shares rose slightly in premarket trading after a Delaware court awarded the company a 30% ongoing royalty ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts ...

Maureen Farrell was a reporter covering initial public offerings and capital markets for the Wall Street Journal in New York.

Psychology Today's online self-tests are intended for informational purposes only and are not diagnostic tools. Psychology Today does not capture or store personally identifiable information, and your ...